These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 24640100)

  • 41. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
    Chen HA; Kuo TC; Tseng CF; Ma JT; Yang ST; Yen CJ; Yang CY; Sung SY; Su JL
    Hepatology; 2016 Nov; 64(5):1637-1651. PubMed ID: 27530187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
    Huang XY; Ke AW; Shi GM; Zhang X; Zhang C; Shi YH; Wang XY; Ding ZB; Xiao YS; Yan J; Qiu SJ; Fan J; Zhou J
    Hepatology; 2013 Jun; 57(6):2235-47. PubMed ID: 23316005
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
    Wang H; Qian Z; Zhao H; Zhang X; Che S; Zhang H; Shang H; Bao J; Hao C; Liu J; Li Z
    Mol Med Rep; 2015 Sep; 12(3):3902-3908. PubMed ID: 26035694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
    Rudalska R; Dauch D; Longerich T; McJunkin K; Wuestefeld T; Kang TW; Hohmeyer A; Pesic M; Leibold J; von Thun A; Schirmacher P; Zuber J; Weiss KH; Powers S; Malek NP; Eilers M; Sipos B; Lowe SW; Geffers R; Laufer S; Zender L
    Nat Med; 2014 Oct; 20(10):1138-46. PubMed ID: 25216638
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
    Godin C; Dupont S; Ezzoukhry Z; Louandre C; Chatelain D; Henaut L; Sabbagh C; Regimbeau JM; Maziere JC; Barbare JC; Chauffert B; Galmiche A
    Anticancer Res; 2013 Apr; 33(4):1415-20. PubMed ID: 23564781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
    Wang Q; Yu T; Yuan Y; Zhuang H; Wang Z; Liu X; Feng M
    J Surg Oncol; 2013 Mar; 107(4):422-7. PubMed ID: 22833259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL
    Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
    Xiao Y; Sun L; Fu Y; Huang Y; Zhou R; Hu X; Zhou P; Quan J; Li N; Fan XG
    BMC Cancer; 2017 Dec; 17(1):857. PubMed ID: 29246127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
    Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
    J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
    Coriat R; Nicco C; Chéreau C; Mir O; Alexandre J; Ropert S; Weill B; Chaussade S; Goldwasser F; Batteux F
    Mol Cancer Ther; 2012 Oct; 11(10):2284-93. PubMed ID: 22902857
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
    Zhou S; Ye W; Duan X; Zhang M; Wang J
    Dig Dis Sci; 2013 Jun; 58(6):1615-26. PubMed ID: 23314856
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
    Liu Y; Lou G; Norton JT; Wang C; Kandela I; Tang S; Shank NI; Gupta P; Huang M; Avram MJ; Green R; Mazar A; Appella D; Chen Z; Huang S
    FASEB J; 2017 Dec; 31(12):5453-5465. PubMed ID: 28821631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
    Nam SW; Park KC; Yang KJ; Lee B; Kim SW
    Int J Oncol; 2014 Oct; 45(4):1450-6. PubMed ID: 25017961
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms.
    Honma Y; Harada M
    J UOEH; 2014 Dec; 36(4):229-35. PubMed ID: 25501753
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
    Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
    Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
    Feng F; Jiang Q; Cao S; Cao Y; Li R; Shen L; Zhu H; Wang T; Sun L; Liang E; Sun H; Chai Y; Li X; Liu G; Yang R; Yang Z; Yang Y; Xin S; Li BA
    Biochim Biophys Acta Gen Subj; 2018 Apr; 1862(4):1017-1030. PubMed ID: 29369785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.